Merck-AstraZeneca breast cancer drug Lynparza improves long-term survival, clinical trial shows | Fortune Well
Lynparza, a drug already FDA-approved for people with a rare form of breast cancer, improves patients’ long-term survival, new clinical trial data suggest.